16α-Bromo-epiandrosterone therapy modulates experimental feline immunodeficiency virus viremia: Initial enhancement leading to long-term suppression

Veterinary Immunology and Immunopathology

Volumn 94, Issue 3-4, 2003, Pages 133-148

  Pedersen, Niels C ^a   North, Thomas W ^a   Rigg, Richard ^b   Reading, Chris ^b   Higgins, Joanne ^a   Leutenegger, Christian ^a   Henderson, Gary L ^c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b HollisEden Pharmaceuticals   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

16 Bromo epiandrosterone; Feline immunodeficiency virus; Immunomodulation

Indexed keywords

16ALPHA BROMOEPIANDROSTERONE; CD4 ANTIGEN; CD8 ANTIGEN; GAMMA INTERFERON; INTERLEUKIN 10; INTERLEUKIN 4; INTERLEUKIN 6; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; PRASTERONE; RANTES; UNCLASSIFIED DRUG; 16 BROMOEPIANDROSTERONE; 16-BROMOEPIANDROSTERONE; ANDROSTERONE; CYTOKINE; DRUG DERIVATIVE; IMMUNOLOGICAL ADJUVANT; MESSENGER RNA; VIRUS ANTIBODY;

ABSORPTION; ANTIBODY RESPONSE; ANTIVIRAL ACTIVITY; ARTICLE; CAT; CAT DISEASE; COHORT ANALYSIS; CONTROLLED STUDY; FECES LEVEL; FELINE IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; LYMPHOCYTE COUNT; MALE; MONONUCLEAR CELL; NEUTROPHIL; NONHUMAN; T LYMPHOCYTE; URINE LEVEL; VIREMIA; VIRUS LOAD; ANIMAL; ANIMAL DISEASE; BIOSYNTHESIS; BLOOD; CD4 CD8 RATIO; CHEMISTRY; DRUG EFFECT; ENZYME LINKED IMMUNOSORBENT ASSAY; FECES; GENETICS; GERMFREE ANIMAL; IMMUNOLOGY; METABOLISM; POLYMERASE CHAIN REACTION; RANDOMIZATION; URINE; VIROLOGY;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

ADJUVANTS, IMMUNOLOGIC; ANDROSTERONE; ANIMALS; ANTIBODIES, VIRAL; CATS; CD4-CD8 RATIO; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FECES; FELINE ACQUIRED IMMUNODEFICIENCY SYNDROME; IMMUNODEFICIENCY VIRUS, FELINE; INTERFERON TYPE II; MALE; POLYMERASE CHAIN REACTION; RANDOM ALLOCATION; RNA, MESSENGER; SPECIFIC PATHOGEN-FREE ORGANISMS; T-LYMPHOCYTES; VIREMIA;

EID: 0142061180     PISSN: 01652427     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0165-2427(03)00081-3     Document Type: Article

References (46)

1. Ansari A.A., Mayne A.E., Sundstrom J.B., Bostik P., Grimm B., Altman J.D., Villinger F. Administration of recombinant rhesus interleukin-12 during acute simian immunodeficiency virus (SIV) infection leads to decreased viral loads associated with prolonged survival in SIVmac251-infected rhesus macaques. J. Virol. 76:2002;1731-1743.
2. Blackbourn D.J., Mackewicz C.E., Barker E., Hunt T.K., Herndier B., Haase A.T., Levy J.A. Suppression of HIV replication by lymphoid tissue CD8+ cells correlates with the clinical state of HIV-infected individuals. Proc. Natl. Acad. Sci. U.S.A. 13:1996;125-130.
3. Bradley W.G., Krus L.A., Good R.A., Day N.K. Dehydroepiandrosterone inhibits replication of feline immunodeficiency virus in chronically infected cells. Vet. Immunol. Immunopath. 46:1995;159-168.
4. Carr D.J. Increased levels of IFN-gamma in the trigeminal ganglion correlate with protection against HSV-1-induced encephalitis following subcutaneous administration with androstenediol. J. Neuroimmunol. 89:1998;160-167.
5. Clerici M., Galli M., Bosis S., Gervasoni C., Moroni M., Norbiato G. Immunoendocrinologic abnormalities in human immunodeficiency virus infection. Ann. N.Y. Acad. Sci. 917:2000;956-961.
6. Dean G.A., Quackenbush S.L., Ackley C.D., Cooper M.D., Hoover E.A. Flow cytometric analysis of T-lymphocyte subsets in cats. Vet. Immunol. Immunopathol. 28:1991;327-335.
7. Du C., Guan Q., Khalil M.W., Sriram S. Stimulation of Th2 response by high doses of dehyroepiandrosterone in KLH-primed splenocytes. Exp. Biol. Med. 226:2001;1051-1060.
8. Dua N., Reubel G., Moore P.F., Higgins J., Pedersen N.C. An experimental study of primary feline immunodeficiency virus infection in cats and a historical comparison to acute simian and human immunodeficiency virus diseases. Vet. Immunol. Immunopathol. 43:1994;337-355.
9. Evans D.T., Desrosiers R.C. Immune evasion stratagies of the primate lentiviruses. Immunol. Rev. 183:2001;141-158.
10. Ferrer J.F., Marshak R.R., Abt D.A., Kenyon S.J. Persistent lymphocytosis in cattle: its cause, nature and relation to lymphosarcoma. Ann. Rech. Vet. 9:1978;851-857.
11. Freilich D., Ferris S., Wallace M., Leach L., Kallen A., Frincke J., Ahlem C., Hacker M., Nelson D., Herbert J. 16α-Bromoepiandrosterone, a dehydroepiandrosterone (DHEA) analogue, inhibits Plasmodium falciparum and Plasmodium berghei growth. Am. J. Trop. Med. Hyg. 63:2000;280-283.
12. Gardner M.B. Retroviruses and wild mice: an historical and personal perspective. Adv. Cancer Res. 65:1994;169-201.
13. Hardy, W.D., Jr., 1993. Feline oncoretroviruses. In: Levy, J.A. (Ed.), The Retroviridae, vol. 2. Plenum Press, New York, pp. 109-180.
14. Hartmann K., Ferk G., North T.W., Pedersen N.C. Toxicity associated with high dosage 9-[(2R-2,5-dihyrdo-5-phosphonomethoxy)-2-furanyl] adenine therapy and attempts to abort early FIV infection. Antiviral Res. 36:1997;11-25.
15. Henderson E., Schwartz A., Pashko L., Abou-Gharbia M., Swern D. Dehydroepiandrosteron and 16 alpha-bromo-epiandrosteron: inhibitors of Epstein-Barr virus-induced transformation of human lymphocytes. Carcinogenesis. 2:1981;683-686.
16. Henderson E., Yang J.Y., Schwartz A. Dehyroepiandrosterone (DHEA) and synthetic DHEA analogs are modest inhibitors of HIV-1 IIIB replication. AIDS Res. Hum. Retroviruses. 8:1992;620-632.
17. Inserra P., Zhang Z., Ardestani S.K., Araghi-Niknam M., Liang B., Jiang S., Shaw D., Militor M., Elliott K., Watson R.R. Modulation of cytokine production by dehydroepiandrosterone (DHEA) plus melatonin (MLT) supplementation of old mice. Proc. Soc. Exp. Biol. Med. 218:1998;76-82.
18. Jacobson M.A., Fusaro R.E., Galmarini M., Lang W. Decreased serum dehydroepiandrosterone is associated with an increased progression of human immunodeficiency virus infection in men with CD4 cell counts of 200-499. J. Infect. Dis. 164:1991;864-868.
19. Johnson R.P., Lifson J.D., Czajak S.C., Cole K.S., Manson K.H., Glickman R., Yang J., Montefiori D.C., Montelaro R., Wyand M.S., Desrosiers R.C. Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. J. Virol. 73:1999;4952-4961.
20. Kent S.J., Ada G.L., Hayes E., Lewis I.M. Determining the immune mechanisms of protection from AIDS: correlates of immunity and the development of syngeneic macaques. Immunol. Rev. 183:2001;94-108.
21. Kurtis J.D., Mtalib R., Onyango F.K., Duffy P.E. Human resistance to Plasmodium falciparum increases after puberty and is predicted by dehyroepiandrosterone levels. Infect. Immun. 69:2001;123-128.
22. Leutenegger C.M., Mislin C.N., Sigrist B., Ehrengruber M.U., Hoffmann-Lehmann R., Lutz H. Quantitative real-time PCR for the measurement of feline cytokine mRNA. Vet. Immunol. Immunopathol. 71:1999;291-305.
23. Levy J.A. The importance of the innate immune system in controlling HIV infection and disease. Trends Immunol. 22:2001;312-316.
24. Levy J.A., Mackewicz C.E., Barker E. Controlling HIV pathogenesis: the role of the noncytotoxic anti-HIV response of CD8+ T cells. Immunol. Today. 17:1996;217-224.
25. Lifson J.D., Rossioi J.L., Piatak M. Jr., Parks T., Li L., Kiser R., Coalter V., Fisher B., Flynn B.M., Czajak S., Hirsch V.M., Reimann K.A., Schmitz J.E., Ghrayeb J., Bischofberger N., Nowak M.A., Desrosiers R.C., Woodarz D. Role of CD8(+) lymphocytes in control of simian immunodeficiency virus infection and resistance to rechallenge after transient early antiretroviral treatment. J. Virol. 75:2001;10187-10199.
26. Locher C.P., Blackbourn D.J., Levy J.A. Suppression of human immunodeficiency virus type 1 replication by a soluble factor produced by CD8+ lymphocytes from HIV-2-infected baboons. Immunol. Lett. 66:1999;151-157.
27. Lockridge K.M., Chien M., Dean G.A., Cole K., Montelero R.C., Luciw P.A., Sparger E.E. Protective immunity against feline immunodeficiency virus induced by inoculation with vif-deleted proviral DNA. Virology. 273:2000;67-79.
28. Loh, P.C., 1993. Spumaviruses. In: Levy, J.A. (Ed.), The Retroviridae, vol. 2, Plenum Press, New York, pp. 361-397.
29. Lohman B.L., McChesney M.B., Miller C.J., McGowan E., Joye S.M., Van Rompay K.K., Reay E., Antipa L., Pedersen N.C., Marthas M.L. A partially attenuated simian immunodeficiency virus induces host immunity that correlates with resistance to pathogenic virus challenge. J. Virol. 68:1994;7021-7029.
30. Loria R.M., Inge T.H., Cook S.S., Szakal A.K., Regelson W. Protection against lethal viral infections with the native steroid dehyroepiandrosterone (DHEA). J. Med. Virol. 26:1988;301-314.
31. Loria R.M., Padgett D.A. Androstenediol regulates systemic resistance against lethal infections in mice. Arch. Virol. 127:1992;103-115.
32. Macy D.W., Hendrick M.J. The potential role of inflammation in the development of postvaccinial sarcomas in cats. Vet. Clin. North Am. Small Anim. Pract. 26:1996;103-109.
33. Mannoor M.K., Weersinghe A., Halder R.C., Reza S., Morshed M., Ariyansinghe A., Watanabe H., Sikikawa H., Abo T. Resistance to malarial infection is achieved by the cooperation of NK1.1(+) and NK1.1(-) subsets of intermediate TCR cells which are constituents of innate immunity. Cell Immun. 211:2001;96-104.
34. Marthas M.L., Ramos R.A., Lohman B.L., Van Rompay K.K., Unger R.E., Miller C.J., Banapour B., Pedersen N.C., Luciw P.A. Viral determinants of simian immunodeficiency virus (SIV) (virulence in rhesus macaques assessed by using attenuated and pathogenic molecular clones of SIVmac. J. Virol. 67:1993;6047-6055.
35. Martin L.N., Murphey-Corb M., Mack P., Baskin G.B., Pantaleo G., Vaccarezza M., Fox C.H., Fauci A.S. Cyclosporin A modulation of early virologic and immunologic events during primary simian immunodeficiency virus infection in rhesus monkeys. J. Infect. Dis. 176:1997;374-383.
36. Obert L.A., Hoover E.A. Relationship of lymphoid lesions to disease course in mucosal feline immunodeficiency virus type C infection. Vet. Pathol. 37:2000;386-401.
37. Padgett D.A., Loria R.M., Sheridan J.F. Endocrine regulation of the immune response to influenza virus infection with a metabolite of DEA-Androstenediol. J. Neuroimmunol. 78:1997;203-211.
38. Pedersen N.C., Theilen G., Keane M.A., Fairbanks L., Mason T., Orser B., Che C.H., Allison C. Studies of naturally transmitted feline leukemia virus infection. Am. J. Vet. Res. 38:1977;1523-1531.
39. Pedersen N.C., Leutenegger C.M., Woo J., Higgins J. Virulence differences between two field isolates of feline immunodeficiency virus (FIV-APetaluma and FIV-CPGammar) in young adult specific pathogen free cats. Vet. Immunol. Immunopathol. 79:2001;53-67.
40. Piketty C., Jayle D., Leplege A., Castiel P., Ecosse E., Gonzalez-Canali G., Sabatier B., Boulle N., Debuire B., Le Bouc Y., Baulieu E.E., Kazatchkine M.D. Double-blind placebo-controlled trial of oral dehydroepiandrosterone in patients with advanced HIV disease. Clin. Endocrinol. 55:2001;325-330.
41. Schinazi, R.F., Eriksson, B.F.H., Arnold, B.H., Lekas, P., McGrath, M.S., 1990. Effect of dehydroepiandrosterone in lymphocytes and macrophages infected with human immunodeficiency viruses. In: Regelson, M.K.W. (Ed.) The Biologic Role of Dehydroepiandrosterone (DHEA). Walter de Gruyer, New York, pp. 157-177.
42. Sugamura, D., Hinuma, Y., 1993. Human retrovirses: HTLV-I and HTLV-II. In: Levy, J.A. (Ed.), The Retroviridae, vol. 2. Plenum Press, New York, pp. 399-435.
43. Torten M., Franchini M., Barlough J.E., George J.W., Mozes E., Lutz H., Pedersen N.C. Progressive immune dysfunction in cats experimentally infected with feline immunodeficiency virus. J. Virol. 65:1991;2225-2230.
44. van Vollenhoven R.F. Dehydroepiandrosterone for the treatment of systemic lupus erythematosus. Expert Opin. Pharmacother. 3:2002;23-31.
45. Yang J.-Y., Schwartz A., Henderson E.E. Inhibition of HIV-1 latency reactivation by dehyroepiandrosterone (DHEA) and an analog of DHEA. Res. Hum. Retroviruses. 9:1993;747-754.
46. Yang B.C., Liu C.W., Chen Y.C., Yu C.K. Exogenous dehydroepiandrosterone modified the expression of T helper-related cytokines in NZB/NZW F1 mice. Immunol. Invest. 27:1998;291-302.